Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue

Oncology Letters

Volumn 10, Issue 1, 2015, Pages 277-282

  Lu, Qingjun ^a   Wang, Jieshu ^a   Yu, Gang ^a   Guo, Tianhua ^a   Hu, Chun ^b   Ren, Peng ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; Immunohistochemistry; Mammalian target of rapamycin 70 KDA ribosomal protein S6 kinase; Reverse transcription polymerase chain reaction

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE;

ADENOCARCINOMA; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

EID: 84929911595     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3228     Document Type: Article

References (34)

1. World Health Organization: The Global Burden of Disease: 2004 Update. World Health Organization, Geneva, 2008.
2. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Otake S, Takeda H, Fujishima S, et al: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 16: 1252-1257, 2010.
4. Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006.
5. Pene F, Claessens YE, Muller O, et al: Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21: 6587-6597, 2002.
6. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
7. Foster DA: Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. Biochim Biophys Acta 1791: 949-955, 2009.
8. Jiang BH and Liu LZ: Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. Drug Resist Updat 11: 63-76, 2008.
9. Wang X and Proud CG: The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 21: 362-369, 2006.
10. Kim EK, Kim HA, Koh JS, et al: Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat 126: 93-99, 2011.
11. Han D, Li SJ, Zhu YT, et al: LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev 14: 4033-4039, 2013.
12. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22: 2336-2347, 2004.
13. O’Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595, 2008.
14. Rizell M, Andersson M, Cahlin C, et al: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13: 66-70, 2008.
15. Benson AB III, Bekaii-Saab T, Chan E, et al; National Comprehensive Cancer Network: Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 11: 519-528, 2013.
16. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 100: 782-788, 2009.
17. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R and Filipits M: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13: 4795-4799, 2007.
18. Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW and Tsao MS: Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer 8: 43, 2008.
19. Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S and Ooi A: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 115: 107-118, 2009.
20. Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063, 2011.
21. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA and Nagle RB: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66: 1203-1212, 2006.
22. Feng W, Duan X, Liu J, Xiao J and Brown RE: Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2: 249-260, 2009.
23. Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A and Duffy MJ: mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors. Breast 21: 178-182, 2012.
24. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’Toole T, Gibbons J, Belldegrun AS and Figlin RA: Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy. Cancer 109: 2257-2267, 2007.
25. Chung JY, Hong SM, Choi BY, Cho H, Yu E and Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15: 660-667, 2009.
26. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC and Xie K: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15: 1821-1829, 2009.
27. Wang D, Chen J, Guo F, Chen H, Duan Z, Wei MY, Xu QM, Wang LH and Zhong MZ: Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas. Asian Pac J Cancer Prev 12: 2581-2584, 2011.
28. No JH, Jeon YT, Park IA, Kang D, Kim JW, Park NH, Kang SB and Song YS: Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit 15: BR301-BR305, 2009.
29. Berven LA, Willard FS and Crouch MF: Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 296: 183-195, 2004.
30. Contessa JN, Hampton J, Lammering G, et al: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21: 4032-4041, 2002.
31. Xiao L, Wang YC, Li WS and Du Y: The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: An immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28: 152, 2009.
32. Zhang Y, Ni HJ and Cheng DY: Prognostic value of phosphorylated mTOR/RPS6KB1 in nonsmall cell lung cancer. Asian Pac J Cancer Prev 14: 3725-3728, 2013.
33. Ji J and Zheng PS: Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 117: 103-108, 2010.
34. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N and Dormond O: Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 9: 57, 2010.